Keep Patients Healthier Longer.

Data saves lives in healthcare today. Those who can effectively transform that data into knowledge are destined to succeed.

New—COVID-19 Complications AlgoMarker

Available now at no cost

That’s where EarlySign comes in.

With the highest level of clinical rigor and development standards, our integrated platform of Machine Learning-based solutions gives healthcare organizations the tools and the power to improve early detection and prevention by identifying subtle, early signs of high-burden diseases in routine clinical data.  

EarlySign clients utilize these extraordinary insights from ordinary data to keep patients healthier longer.

Moving from sick care to health care

EarlySign’s team is driven by a single goal: Help the medical community identify and connect with those who would benefit from early detection and prevention of high-burden diseases, moving patients from sick care to health care.

The result: increased potential to prevent or delay progression to high-burden illness.

AlgoMarkers™

Each AlgoMarker™ is a condition-specific clinical predictor used by healthcare organizations to identify patients at high-risk for developing or harboring high burden disease. AlgoMarkers™ analyze routine, available lab results and clinical data to provide personalized health trajectory insights.

AlgoAnalyzer™

AlgoAnalyzer™ is a server-side software platform for running various healthcare calculators, including patient-specific algorithmic and predictive models called AlgoMarkers™ AlgoAnalyzer™ is designed to integrate easily into clinical laboratory (LIS) and population health management IT ecosystems and workflows.

Who we help

solutions for

Identify patients on high-risk trajectories, helping providers prevent or delay disease progression.

solutions for

Enable value-based transformation of laboratory medicine with patient-specific insights and risk stratification. This helps physicians, providers and payors find opportunities to efficiently deliver care.

solutions for

Flag eligible populations for clinical trials, identify cohorts for therapeutic efforts, and work with clinical partners.

Are you looking to solve high-burden disease challenges?